Avoro Capital Advisors LLC
CIK 1633313 · View on SEC EDGAR ↗
- Portfolio value
- $11.1B
- Positions
- 26
- As of
- June 30, 2026
#447 of 9,443 by 13F value · top 4.7%
Portfolio value QoQ: +9.6% 13F does not disclose cash
- Top 10 holdings weight
- 79.46%
- Top 25 holdings weight
- 99.94%
- Positions above 1%
- 17
- Effective number of positions
- 12.7
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 18.29% Est. buys $1,947,183,061 · sells $2,546,491,102
Median holding: 3.0 quarters Tracked Q4 2024–Q2 2026 · 39.4% still held
- New positions
- 3
- Increased
- 11
- Decreased
- 3
- Closed
- 7
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- High-conviction bets The holdings this manager is most concentrated in.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +46.8% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 95.2% · Options excluded: 0.0%
Sector breakdown
Healthcare
84.1%
Other/Unmapped
15.9%
Full portfolio 26 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics Corporation - Common Stock | $1,505,082,912 | 13.52% | 2,777,777 | $-54,454,488 | Up ×3 | ||
| Unknown issuer (CUSIP: K08588103) | $1,363,235,526 | 12.24% | 5,111,111 | Up ×1 | |||
| KRYS Krystal Biotech, Inc. - Common Stock | $1,073,713,003 | 9.64% | 2,888,888 | $327,455,455 | |||
| MDGL Madrigal Pharmaceuticals, Inc. - Common Stock | $984,408,154 | 8.84% | 1,833,333 | $32,644,946 | Up ×2 | ||
| ARGX argenx SE - American Depositary Shares | $927,770,000 | 8.33% | 1,000,000 | $197,520,000 | |||
| ARWR Arrowhead Pharmaceuticals, Inc. - Common Stock | $925,591,288 | 8.31% | 11,355,555 | $254,701,351 | Up ×2 | ||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $857,129,238 | 7.70% | 7,474,747 | $234,557,560 | |||
| RVMD Revolution Medicines, Inc. - Common Stock | $430,182,160 | 3.86% | 2,297,000 | $202,184,981 | Down ×1 | ||
| CYTK Cytokinetics, Incorporated - Common Stock | $425,949,915 | 3.82% | 4,999,999 | $206,249,937 | Up ×1 | ||
| CELC Celcuity Inc. - Common Stock | $355,708,000 | 3.19% | 3,400,000 | $-29,514,500 | Up ×2 | ||
| GPCR Structure Therapeutics Inc. - American Depositary Shares | $351,836,637 | 3.16% | 6,555,555 | $35,858,886 | |||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $348,746,620 | 3.13% | 5,777,777 | $12,768,887 | |||
| DFTX Definium Therapeutics, Inc. - Common Shares | $338,165,292 | 3.04% | 7,188,888 | $243,665,292 | Up ×1 | ||
| QURE uniQure N.V. - Ordinary Shares | $309,881,409 | 2.78% | 6,727,777 | $212,442,031 | Up ×1 | ||
| VERA Vera Therapeutics, Inc. - Class A Common Stock | $245,612,034 | 2.21% | 5,723,888 | $8,702,070 | Down ×1 | ||
| TSHA Taysha Gene Therapies, Inc. - Common Stock | $162,683,327 | 1.46% | 23,888,888 | $65,684,327 | Up ×1 | ||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $123,142,800 | 1.11% | 12,540,000 | $18,834,750 | Up ×4 | ||
| GLTO Galecto, Inc. - Common Stock | $98,395,830 | 0.88% | 3,783,000 | $416,130 | |||
| Unknown issuer (CUSIP: 423494103) | $70,710,760 | 0.63% | 1,925,150 | Up ×1 | |||
| GHRS GH Research PLC - Ordinary Shares | $48,384,000 | 0.43% | 1,800,000 | $23,076,000 | |||
| VRDN Viridian Therapeutics, Inc. - Common Stock | $45,925,000 | 0.41% | 2,500,000 | $16,585,000 | Up ×1 | ||
| SEPN Septerna, Inc. - Common Stock | $44,792,875 | 0.40% | 1,337,500 | $12,652,750 | |||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $43,119,994 | 0.39% | 2,333,333 | $22,068,694 | Up ×1 | ||
| SNSE Sensei Biotherapeutics, Inc. - Common Stock | $36,100,975 | 0.32% | 1,444,039 | Up ×1 | |||
| WHWK Whitehawk Therapeutics, Inc. - Common Stock | $13,050,261 | 0.12% | 2,849,402 | $3,219,824 | |||
| LXEO Lexeo Therapeutics, Inc. - Common Stock | $6,932,175 | 0.06% | 1,489,189 | $-3,830,325 | Down ×2 | ||
| No matches | |||||||
Conviction holdings
Positions increased for 3+ consecutive quarters.
Share counts are as reported in 13F filings (not split-adjusted)
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: K08588103) | $1,363,235,526 | 5,111,111 | 12.24% |
| Unknown issuer (CUSIP: 423494103) | $70,710,760 | 1,925,150 | 0.63% |
| SNSE | $36,100,975 | 1,444,039 | 0.32% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| KRYS | Price move only | +0 | +$327.5M |
| ARWR | Bought more | +656K | +$254.7M |
| DFTX | Bought more | +2.2M | +$243.7M |
| KYMR | Price move only | +0 | +$234.6M |
| QURE | Bought more | +768K | +$212.4M |
| CYTK | Bought more | +1.7M | +$206.2M |
| RVMD | Trimmed | -47K | +$202.2M |
| ARGX | Price move only | +0 | +$197.5M |
| TSHA | Bought more | +2.2M | +$65.7M |
| UTHR | Bought more | +148K | -$54.5M |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| ASND | June 30, 2026 | 5,062,500 | $1,157,945,625 | -3.3% |
| APLS | June 30, 2026 | 12,222,222 | $491,699,991 | No longer tracked |
| CNTA | June 30, 2026 | 11,430,455 | $454,017,673 | No longer tracked |
| RNA | March 31, 2026 | 5,455,000 | $393,469,150 | -1.8% |
| MRUS | Dec. 31, 2025 | 3,542,500 | $333,526,375 | No longer tracked |
| TERN | June 30, 2026 | 5,695,000 | $300,240,400 | No longer tracked |
| XBI | March 31, 2026 | 2,100,000 | $256,053,000 | No longer tracked |
| AKRO | Dec. 31, 2025 | 3,955,555 | $187,809,751 | No longer tracked |
| SRPT | June 30, 2025 | 2,674,835 | $170,707,970 | 14.4% |
| TRML | Dec. 31, 2025 | 2,555,555 | $122,232,196 | No longer tracked |
| FOLD | Dec. 31, 2025 | 15,025,000 | $118,397,000 | No longer tracked |
| BMRN | March 31, 2025 | 1,462,500 | $96,130,125 | -4.3% |
| ETNB | Dec. 31, 2025 | 6,387,790 | $93,900,513 | No longer tracked |
| ITCI | June 30, 2025 | 625,000 | $82,450,000 | No longer tracked |
| SLNO | June 30, 2026 | 2,300,000 | $77,004,000 | No longer tracked |
| MNMD | March 31, 2026 | 5,000,000 | $66,950,000 | No longer tracked |
| PTCT | March 31, 2026 | 685,000 | $52,032,600 | 3.6% |
| BPMC | Sept. 30, 2025 | 375,000 | $48,067,500 | No longer tracked |
| ALKS | June 30, 2026 | 1,200,000 | $42,432,000 | -8.3% |
| ORKA | March 31, 2026 | 1,333,340 | $40,413,535 | 118.0% |
| PCVX | June 30, 2025 | 1,000,000 | $37,760,000 | 91.6% |
| APGE | March 31, 2026 | 500,000 | $37,740,000 | 60.2% |
| SNDX | March 31, 2025 | 2,275,000 | $30,075,500 | 61.2% |
| IOVA | March 31, 2025 | 3,500,000 | $25,900,000 | 169.8% |
| CGON | March 31, 2025 | 700,000 | $20,076,000 | 219.5% |
| KURA | March 31, 2025 | 2,250,000 | $19,597,500 | 78.6% |
| GLUE | Sept. 30, 2025 | 3,725,000 | $16,799,750 | 101.3% |
| AUTL | June 30, 2025 | 9,910,642 | $15,361,495 | 8.4% |
| RCKT | March 31, 2025 | 1,200,000 | $15,084,000 | -47.1% |
| MLTX | Dec. 31, 2025 | 2,000,000 | $14,340,000 | 20.3% |
| INCY | March 31, 2026 | 135,000 | $13,333,950 | 35.5% |
| RARE | Sept. 30, 2025 | 330,000 | $11,998,800 | -13.2% |
| OLMA | March 31, 2025 | 1,651,982 | $9,631,055 | 197.3% |
| BCRX | Dec. 31, 2025 | 1,250,000 | $9,487,500 | 25.8% |
| MNKD | June 30, 2026 | 2,200,000 | $5,390,000 | 1.1% |
| TNGX | Dec. 31, 2025 | 545,000 | $4,578,000 | 171.3% |